{"id":2981,"date":"2025-10-01T14:24:52","date_gmt":"2025-10-01T12:24:52","guid":{"rendered":"https:\/\/tetraneuron.wpenginepowered.com\/?post_type=team_members&#038;p=2981"},"modified":"2025-10-17T12:21:28","modified_gmt":"2025-10-17T10:21:28","slug":"pedro-bermejo-md-phd","status":"publish","type":"team_members","link":"https:\/\/tetraneuron.com\/en\/team_members\/pedro-bermejo-md-phd\/","title":{"rendered":"Pedro Bermejo, MD, PhD"},"content":{"rendered":"<p>Dr. Pedro Bermejo is Head of Gene Therapy in the pharmaceutical industry, with a PhD in medicine from the Autonomous University of Madrid and specialization in Neurology. He has worked as a neurologist in top Madrid hospitals, completed executive and medical management studies, and held roles at major pharmaceutical companies including Sandoz (Germany), WCG (United States), Oryzon (Barcelona), TFS (Sweden), and UCB (Belgium). Dr. Bermejo has also co-founded the Xana Innovation and Xana Stim healthcare innovation firms and served as a lecturer, publishing extensively in the field.<\/p>\n","protected":false},"featured_media":3044,"template":"","team-type":[],"class_list":["post-2981","team_members","type-team_members","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/team_members\/2981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/team_members"}],"about":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/types\/team_members"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/media\/3044"}],"wp:attachment":[{"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/media?parent=2981"}],"wp:term":[{"taxonomy":"team-type","embeddable":true,"href":"https:\/\/tetraneuron.com\/en\/wp-json\/wp\/v2\/team-type?post=2981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}